Rudra Chhajer1, Anirban Bhattacharyya1, Nicky Didwania1, Md Shadab1, Nirupam Das2, Partha Palit2, Tushar Vaidya3, Nahid Ali4. 1. Infectious Diseases and Immunology Division, Council of Scientific and Industrial Research (CSIR), Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Jadavpur, Kolkata 700032, West Bengal, India. 2. Assam University, Silchar (A Central University), Dept. of Pharmaceutical Science, Division of Drug Discovery Lab, Silchar 788011, Assam, India. 3. Council of Scientific and Industrial Research (CSIR), Centre for Cellular and Molecular Biology, Uppal Road, Habshiguda, Hyderabad 500007, Telangana, India. 4. Infectious Diseases and Immunology Division, Council of Scientific and Industrial Research (CSIR), Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Jadavpur, Kolkata 700032, West Bengal, India. Electronic address: nali@iicb.res.in.
Abstract
BACKGROUND: Aurora kinases are key mitotic kinases executing multiple aspects of eukaryotic cell-division. The apicomplexan homologs being essential for survival, suggest that the Leishmania homolog, annotated LdAIRK, may be equally important. METHODS: Bioinformatics, stage-specific immunofluorescence microscopy, immunoblotting, RT-PCR, molecular docking, in-vitro kinase assay, anti-leishmanial activity assays, flow cytometry, fluorescence microscopy. RESULTS: Ldairk expression is seen to vary as the cell-cycle progresses from G1 through S and finally G2M and cytokinesis. Kinetic studies demonstrate their enzymatic activity exhibiting a Km and Vmax of 6.12μM and 82.9pmoles·min(-1)mg(-1) respectively against ATP using recombinant Leishmania donovani H3, its physiological substrate. Due to the failure of LdAIRK-/+ knock-out parasites to survive, we adopted a chemical knock-down approach. Based on the conservation of key active site residues, three mammalian Aurora kinase inhibitors were investigated to evaluate their potential as inhibitors of LdAIRK activity. Interestingly, the cell-cycle progressed unhindered, despite treatment with GSK-1070916 or Barasertib, inhibitors with greater potencies for the ATP-binding pocket compared to Hesperadin, which at nanomolar concentrations, severely compromised viability at IC50s 105.9 and 36.4nM for promastigotes and amastigotes, respectively. Cell-cycle and morphological studies implicated their role in both mitosis and cytokinesis. CONCLUSION: We identified an Aurora kinase homolog in L. donovani implicated in cell-cycle progression, whose inhibition led to aberrant changes in cell-cycle progression and reduced viability. GENERAL SIGNIFICANCE: Human homologs being actively pursued drug targets and the observations with LdAIRK in both promastigotes and amastigotes suggest their potential as therapeutic-targets. Importantly, our results encourage the exploration of other proteins identified herein as potential novel drug targets.
BACKGROUND: Aurora kinases are key mitotic kinases executing multiple aspects of eukaryotic cell-division. The apicomplexan homologs being essential for survival, suggest that the Leishmania homolog, annotated LdAIRK, may be equally important. METHODS: Bioinformatics, stage-specific immunofluorescence microscopy, immunoblotting, RT-PCR, molecular docking, in-vitro kinase assay, anti-leishmanial activity assays, flow cytometry, fluorescence microscopy. RESULTS: Ldairk expression is seen to vary as the cell-cycle progresses from G1 through S and finally G2M and cytokinesis. Kinetic studies demonstrate their enzymatic activity exhibiting a Km and Vmax of 6.12μM and 82.9pmoles·min(-1)mg(-1) respectively against ATP using recombinant Leishmania donovani H3, its physiological substrate. Due to the failure of LdAIRK-/+ knock-out parasites to survive, we adopted a chemical knock-down approach. Based on the conservation of key active site residues, three mammalian Aurora kinase inhibitors were investigated to evaluate their potential as inhibitors of LdAIRK activity. Interestingly, the cell-cycle progressed unhindered, despite treatment with GSK-1070916 or Barasertib, inhibitors with greater potencies for the ATP-binding pocket compared to Hesperadin, which at nanomolar concentrations, severely compromised viability at IC50s 105.9 and 36.4nM for promastigotes and amastigotes, respectively. Cell-cycle and morphological studies implicated their role in both mitosis and cytokinesis. CONCLUSION: We identified an Aurora kinase homolog in L. donovani implicated in cell-cycle progression, whose inhibition led to aberrant changes in cell-cycle progression and reduced viability. GENERAL SIGNIFICANCE: Human homologs being actively pursued drug targets and the observations with LdAIRK in both promastigotes and amastigotes suggest their potential as therapeutic-targets. Importantly, our results encourage the exploration of other proteins identified herein as potential novel drug targets.
Authors: Victor Sebastián-Pérez; Paula Martínez de Iturrate; Montserrat Nácher-Vázquez; Luis Nóvoa; Concepción Pérez; Nuria E Campillo; Carmen Gil; Luis Rivas Journal: Biomedicines Date: 2022-05-14
Authors: Joyce V B Borba; Arthur C Silva; Pablo I P Ramos; Nathalia Grazzia; Danilo C Miguel; Eugene N Muratov; Nicholas Furnham; Carolina H Andrade Journal: Comput Struct Biotechnol J Date: 2019-02-08 Impact factor: 7.271
Authors: N Baker; C M C Catta-Preta; R Neish; J Sadlova; B Powell; E V C Alves-Ferreira; V Geoghegan; J B T Carnielli; K Newling; C Hughes; B Vojtkova; J Anand; A Mihut; P B Walrad; L G Wilson; J W Pitchford; P Volf; J C Mottram Journal: Nat Commun Date: 2021-02-23 Impact factor: 14.919
Authors: Belinda J Morahan; Clarissa Abrie; Keith Al-Hasani; Mitchell B Batty; Victoria Corey; Anne N Cowell; Jandeli Niemand; Elizabeth A Winzeler; Lyn-Marie Birkholtz; Christian Doerig; Jose F Garcia-Bustos Journal: Commun Biol Date: 2020-11-20